Genome-wide association study of phenotypes measuring progression from first cocaine or opioid use to dependence reveals novel risk genes-Reference-Cited by-同舟云学术

Genome-wide association study of phenotypes measuring progression from first cocaine or opioid use to dependence reveals novel risk genes

Published:2021-02-28 Issue: Volume: Page:
ISSN:2692-3106
Container-title:Exploration of Medicine
language:
Short-container-title:

Author:

Sherva Richard¹,Zhu Congcong¹,Wetherill Leah²,Edenberg Howard J.³,Johnson Emma⁴,Degenhardt Louisa⁵,Agrawal Arpana⁴,Martin Nicholas G.⁶,Nelson Elliot⁴,Kranzler Henry R.⁷,Gelernter Joel⁸,Farrer Lindsay A.⁹

Affiliation:

1. Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, MA 02118, USA

2. Department of Medical and Molecular Genetics and Biochemistry, Indiana University School of Medicine, Indianapolis, IN 46202, USA

3. Department of Medical and Molecular Genetics and Biochemistry, Indiana University School of Medicine, Indianapolis, IN 46202, USA 3Department of Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA

4. Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO 63110, USA

5. National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW 2052, Australia

6. Queensland Institute of Medical Research Berghofer, Brisbane, QLD 4006, Australia

7. Perelman School of Medicine, University of Pennsylvania and VISN 4 MIRECC, Crescenz VAMC, Philadelphia, PA 19104, USA

8. Departments of Psychiatry, Genetics and Neuroscience, Yale School of Medicine, New Haven, CT 06511, USA 9Department of Psychiatry, VA CT Healthcare Center, West Haven, CT 06516, USA

9. Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, MA 02118, USA；Department of Neurology, Boston University School of Medicine, Boston, MA 02118, USA 11Department of Ophthalmology, Boston University School of Medicine, Boston, MA 02118, USA 12Department of Epidemiology, Boston University School Public Health, Boston, MA 02118, USA 13Department of Biostatistics, Boston University School Public Health, Boston, MA 02118, USA

Abstract

Aim: Substance use disorders (SUD) result in substantial morbidity and mortality worldwide. Opioids, and to a lesser extent cocaine, contribute to a large percentage of this health burden. Despite their high heritability, few genetic risk loci have been identified for either opioid or cocaine dependence (OD or CD, respectively). A genome-wide association study of OD and CD related phenotypes reflecting the time between first self-reported use of these substances and a first DSM-IV dependence diagnosis was conducted. Methods: Cox proportional hazards regression in a discovery sample of 6,188 African-Americans (AAs) and 6,835 European-Americans (EAs) participants in a genetic study of multiple substance dependence phenotypes were used to test for association between genetic variants and these outcomes. The top findings were tested for replication in two independent cohorts. Results: In the discovery sample, three independent regions containing variants associated with time to dependence at P < 5 x 10-8 were identified, one (rs61835088 = 1.03 x 10-8) for cocaine in the combined EA-AA meta-analysis in the gene FAM78B on chromosome 1, and two for opioids in the AA portion of the sample in intergenic regions of chromosomes 4 (rs4860439, P = 1.37 x 10-8) and 9 (rs7032521, P = 3.30 x 10-8). After meta-analysis with data from the replication cohorts, the signal at rs61835088 improved (HR = 0.87, P = 3.71 x 10-9 and an intergenic SNP on chromosome 21 (rs2825295, HR = 1.14, P = 2.57 x 10-8) that missed the significance threshold in the AA discovery sample became genome-wide significant (GWS) for CD. Conclusions: Although the two GWS variants are not in genes with obvious links to SUD biology and have modest effect sizes, they are statistically robust and show evidence for association in independent samples. These results may point to novel pathways contributing to disease progression and highlight the utility of related phenotypes to better understand the genetics of SUDs.

Publisher

Open Exploration Publishing

Reference58 articles.

1. GBD 2016 Alcohol and Drug Use Collaborators. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018;5:987-1012.

2. Rummans TA, Burton MC, Dawson NL. How good intentions contributed to bad outcomes: the opioid crisis. Mayo Clin Proc. 2018;93:344-50.

3. Case A, Deaton A. Mortality and morbidity in the 21st century. Brookings Pap Econ Act. 2017;2017:397-476.

4. Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet. 2019;394:1560-79.

5. Clark CB, Zyambo CM, Li Y, Cropsey KL. The impact of non-concordant self-report of substance use in clinical trials research. Addict Behav. 2016;58:74-9.